Patrick N. of Affinity Asset Advisors was asked if the end of 2023 were allegedly the best months in biotech history. “It was a painful preceding few years,” he said. “It feels like the time is probably around now when we start to see people becoming more interested in the sector again. It’s exciting as a biotech investor. Obviously, these companies are going to help people down the road, and they need to be able to raise money to do that, and hopefully with a better market environment that can happen.” Key to long-term success is the ability to accurately model uncertainty. This is why we created our advanced digital PROVEN ™ platform. Check out the full interview with Nosker (part of the SF Healthcare Week conference) here: https://lnkd.in/g8ad4zNV #HEOR #Innovation #BioPharma #HealthEconomics
𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: A buy side perspective of biotech with Affinity Asset Advisors' Patrick N.. Patrick Nosker gives his take on today's conference news and highlights the science behind some of his firm's top holdings like Apogee, Teva, CymaBay, and Madrigal. Full video: https://lnkd.in/g8ad4zNV BiotechTV's coverage of SF Healthcare Week is brought to you by: HSBC Innovation Banking.
